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ABSTRACT: Liver transplantation is the primary treatment for various end-stage hepatic 
diseases but is hindered by the lack of donor organs, complications associated with 
rejection and immunosuppression. An increasingly unbridgeable gap exists between the 
supply and demand of transplantable organs. Hence stem cell research and regenerative 
medicine have the potential to revolutionize the future of medicine with the ability to 
regenerate damaged and diseased organs. Stem cells serving as a repair system for the 
body, can theoretically divide without limit to replenish other cells. These cells could 
relieve the symptoms of liver disease or the genetic error could potentially be corrected by 
gene therapy. In cases of acute liver failure in adults, stem cell therapies might be used to 
support the liver, allowing it time to recover. 
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INTRODUCTION
ᴪ 
 
The global health burden from liver disease is 
immense with over 450 million individuals infected 
with viral hepatitis and hepatocellular carcinoma 
(HCC)
1. Cirrhosis kills 27,000 Americans each 
year, and over 25 million Americans have liver-
related diseases. The World Health Organization 
estimates that there are at least 21.3 million 
hepatitis C virus (HCV) carriers in the Eastern 
Mediterranean countries, which is close to the 
number of carriers estimated in the Americas and 
Europe combined
2. It is estimated that of the 
world’s six billion people, one third (two billion) 
have been infected with Hepatitis B virus (HBV)
3. 
HBV is thought to be responsible for more than 
350 million HBV carriers in the world, with an 
annual mortality rate of one million patients
4. 
Studies in Saudi Arabia have shown HBV is the 
most predominant type of hepatitis, accounting for 
49.3% of the cases, followed by HCV (40.7%) and 
HAV (10%).  HBV predominates in young adults 
(31-50 years), and HCV in older adults (51-70 
years)
5.  Approximately 20% of Hepatitis C 
infected individuals progress to end stage liver 
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disease and there are currently nearly 17,000 
people waiting for a liver transplant in the United 
States. This shortage of donor livers exists 
worldwide and has prompted the search for 
alternative cell therapies for intractable liver 
disease
6. 
The hope that many diseases can someday be 
treated with stem cell therapy is inspired by the 
historical success of bone marrow transplants in 
improving the long-term survival of patients with 
leukemia and other cancers, inherited blood 
disorders, and diseases of the immune system. 
Nearly 40 years ago, the cell type responsible for 
those successes was identified as the hematopoietic 
stem cell
7.  The ability of hematopoietic stem cells 
(HSCs) to self-renew continuously in the marrow 
and to differentiate into the full complement of cell 
types found in blood qualifies them as the premier 
adult stem cells. 
 
BACKGROUND 
 
The possibility that the human body contains cells 
that can repair and regenerate damaged and 
diseased tissue is rapidly developing into a new 
clinical ‘tool’ with huge potential. Stem cells are 
basic cells of all multicellular organisms having the 
potential to differentiate into a wide range of adult 
cells (Table 1).  Stem cells can be classified into 
three broad categories, based on their ability to  Akhtar et al / Stem cells and liver disease 
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differentiate. Totipotent stem cells are found only 
in early embryos. Each cell can form a complete 
organism (e.g., identical twins). Pluripotent stem 
cells exist in the undifferentiated inner cell mass of 
the blastocyst and can form any of the over 200 
different cell types found in the body. Multipotent 
stem cells are derived from fetal tissue, cord blood, 
and adult stem cells. Although their ability to 
differentiate is more limited than pluripotent stem 
cells, they already have a track record of success in 
cell-based therapies
8. The term, “plasticity” has 
been coined to emphasize the process in which 
pluripotent stem cells are able to differentiate into 
multiple cell lineages, and is supported by the 
finding of intrahepatic chimerism in transplant 
recipients as well as the apparent repopulation of 
injured livers with bone marrow derived cells.  The 
term, “transdifferentiation”, is used to focus on 
differentiation of cells from one organ specific 
lineage to those of another organ
9. 
 
Table 1: Differential potential ranges of Different Stem Cells 
 
Differentiation  Number of cell 
types  Example of stem cell  Cell types resulting from 
differentiation 
Totipotent  All  Zygote, blastomere   All cell types  
Pleuripotent 
All except cells of 
the embryonic 
membranes 
Embryonic Stem cells  Cells from all three germ 
layers 
Multipotent  Many  Hematopoietic cells  
skeletal muscle, cardiac 
muscle, liver cells, all blood 
cells 
Oligopotent  Few Myeloid  precursor 
5 types of blood cells 
(Monocytes, macrophages, 
eosinophils, neutrophils, 
erythrocytes) 
Quadripotent  4  Mesenchymal progenitor 
cell 
Cartilage cells, fat cells, 
stromal cells, bone-forming 
cells 
Tripotent  3 Glial-restricted  precursor  2 types of astrocytes, 
oligodendrocytes 
Bipotent  2  Bipotential precursor from 
murine fetal liver   B cells, macrophages 
Unipotent  1  Mast cell precursor  Mast cells 
Nullipotent  None  Terminally differentiated 
cell e.g. Red blood cell  No cell division 
 
ETHICAL CONTROVERSY 
  
Basic work on human stem cells and their possible 
applications require an ample supply of the cells 
from a variety of genetically diverse viable cell 
lines. To date, pluripotent stem cells, from embryos 
or fetuses, have seemed potentially the most 
promising for medical applications, but obtaining 
them entails the destruction of an embryo or fetus, 
which touches on ethical issues concerning   
abortion
10. Additional issues are  cloning of 
humans, a technology that conceivably could be 
used to produce embryos to supply stem cells. 
Efforts are being directed to the use of adult stem 
cells, obtained from developed tissue (regardless of 
the age of the organism). These appear to be 
multipotent and give rise to specialized cells 
needed by the body for tissue regeneration after the 
organism develops beyond the embryonic stage, 
and they generally produce cell types found in the 
tissue in which they reside
11,12. 
 
CELL CULTURE 
 
An essential prerequisite to the successful 
development of stem cell-based therapies is the 
development of techniques to propagate pure 
populations of stem cells on a large scale. 
Mesenchymal stem cells are very rare, existing at 
an estimated frequency of about 1 in 100,000 bone 
marrow cells
13. To obtain sufficient numbers, cells 
are encouraged to multiply indefinitely in the 
laboratory. Briefly, the process entails isolating 
cells from a source such as umbilical cord and 
growing them in a cell culture facility whereby the   
cells are expanded over several population  Akhtar et al / Stem cells and liver disease 
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doublings. Mesenchymal stem cells are 
traditionally grown on a fibroblast feeder layer that 
provides them with the necessary chemical signals 
to remain undifferentiated and to continue dividing 
over and over. After expansion these cells retain 
their ability to differentiate into a variety of mature 
cell types
14.  It had been thought previously that 
stem cells are directly influenced by cells in the 
local environment or ‘niche’, but Canadian 
researchers have recently demonstrated that human 
embryonic stem cells can actually produce 
distinctive niche cells in vitro, which then release 
stem cell nourishing proteins to help maintain the 
‘parent’ cells
15. The niche represents a route for 
modifying stem cell behaviour. If human stem cells 
can be reliably guided down a particular pathway, 
then they can be more readily used for future 
clinical therapy to regenerate damaged tissue
16.  
 
LIVER DISEASE 
 
Liver cirrhosis in humans represents the end stage 
of chronic
 liver injury and is characterized
 by the 
disorganized proliferation of hepatocytes and 
biliary
  cells, excessive scarring, and loss of the 
three-dimensional
 architecture of the hepatic lobule, 
which leads to chronic liver
  failure eventually 
requiring transplantation. The risk of developing 
hepatocellular carcinoma is significantly increased 
in patients with hepatitis virus infection, alcoholic 
liver disease, or genetic hemochromatosis
17. 
 
CELL REPAIR 
 
Liver regeneration is a complex phenomenon 
involving the proliferation of different cell lineages 
in response to damage such as after liver resection; 
it is the hepatocytes themselves which act as the 
stem cell reserve, proliferating to replace the lost 
liver mass. But in situations where the hepatocytes 
are prevented from dividing, and in some disease 
states, other cells derived from the terminal bile 
ductules and called oval cells, appear, and these are 
capable of providing both biliary epithelium and 
hepatocytes
18,19. 
The extent of progenitor cell activation and the 
direction of differentiation are correlated with the 
severity of the disease and the type of mature 
epithelial cell (hepatocyte or bile duct epithelial 
cell), respectively, that is damaged. Analogous to 
findings in animal models of hepatocarcinogenesis, 
human hepatic progenitor cells most likely can give 
rise to hepatocellular carcinoma
20. 
Oval cells appear to reside in the smallest units of 
the bile duct epithelium within the periportal 
region, termed the canals of Hering and/or 
periductular region, from which they can migrate 
into the liver parenchyma. Oval cells, which 
express immature hepatocyte markers, such as α-
fetoprotein,  γ-glutamyl-transferase, albumin, K19, 
OV-6, and OC.2, as well as several hematopoietic 
cell markers, such as CD34, Thy1.1, Flt3-receptor, 
and Kit, can give rise to both hepatocytes and bile 
ductular cells in vitro and in vivo. In particular, the 
signaling networks involving HGF, EGF/TGF-α, 
vascular endothelial growth factor (VEGF), SCF, 
Wnt/β-catenin, TGF-β, and stromal-derived factor-
1 (SDF-1) appear to assume a critical role in the 
regulation of the proliferation, survival, and 
differentiation of oval cells into hepatocytes during 
hepatic regeneration
21.  
Mito and Kusano
22 were the first to attempt 
hepatocyte transplantation in cirrhotic patients. 
Hepatocytes were isolated from the segments of the 
cirrhotic livers of the patients and transplanted by 
injection into the splenic pulp, splenic artery, 
splenic vein, or portal vein. Although the injections 
were tolerated well and there was some evidence of 
improvement in encephalopathy, protein synthesis, 
and renal function, the ultimate clinical outcome 
was not altered significantly. This study was a 
landmark for taking hepatocyte transplantation into 
clinics
23. 
Many other growth factors and cytokines, such as 
EGF, TGF, IL-6, and TNF stimulate mitogenesis. 
Co-mitogenic factors such as estrogen, glucagon, 
and insulin upregulate the activity of mitogenic 
factors and can accelerate the liver regeneration 
process. Prolonged stimulation by some 
hepatotrophic factors can lead to hypertrophy or 
development of neoplasms. Prolonged intake of 
estrogen, mainly in the form of high–dose oral 
contraceptives or anabolic steroids, is associated 
with the development of hepatocellular adenomas 
and an increased risk for the development of 
hepatocellular carcinoma
24. 
Isolation of hepatic progenitors from a human 
source is a major challenge for the clinical 
application of this therapy. Intrahepatic sources 
include cadaver livers that are considered of 
insufficient quality for organ transplantation. 
Hepatocytes isolated from aborted human fetuses 
are another potential source
25. Extra-hepatic 
sources include autologous bone marrow, umbilical 
cord blood, Wharton’s jelly, peripheral blood 
monocytes
26,27.  Programmable cells of monocytic 
origin are capable of differentiating into 
neohepatocytes, which closely resemble primary 
human hepatocytes with respect to morphology, 
expression of hepatocyte markers, and specific 
metabolic functions. After transplantation into the 
liver of severe combined immunodeficiency 
disease/non-obese diabetic mice, neohepatocytes 
integrated well into the liver tissue and showed a 
morphology and albumin expression similar to that 
of primary human hepatocytes transplanted under 
identical conditions. Programmable cells of 
monocytic origin-derived pancreatic neoislets 
expressed  β cell-specific transcription factors, 
secreted insulin and C peptide in a glucose- Akhtar et al / Stem cells and liver disease 
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dependent manner, and normalized blood glucose 
levels when xenotransplanted into 
immunocompetent, streptozotocin-treated diabetic 
mice The ability to reprogram, expand, and 
differentiate peripheral blood monocytes in large 
quantities opens the real possibility of the clinical 
application of programmable cells of monocytic 
origin in tissue repair and organ regeneration
28,29.  
Liver stem cells can be transplanted through 
several routes:  Intraperitoneal, and percutaneous 
intrahepatic artery catheterization in acute liver 
failure, and umbilical vein catheterization, 
percutaneous   intrahepatic route, and portal vein or 
intrahepatic artery catheterization in metabolic liver 
diseases
30.  Intrasplenic artery, hepatic artery and 
portal vein catheterization in chronic liver 
diseases
31. Attempts have been made to infuse cells 
from autologous bone marrow along with 
granulocyte stimulating factor. The preferred route 
is hepatic artery catheterization
32. 
 
STEM CELL THERAPY 
 
The bone marrow is a potential source of 
multipotential stem cells. Bone marrow stem cells 
expressing hematopoietic antigens have been 
proven to have the capacity to differentiate into 
hepatocytes
33. Previous attempts to isolate 
hepatocyte progenitors from bone marrow have 
resulted in a mixture of liver and hematopoietic 
progenitor cells. These cells share common cell 
surface receptors and antigens
34. 
Hematopoietic stem cells (HSCs) and 
mesenchymal stem cell (MSCs) are two main 
subtypes of bone marrow stem cells.  The diseased 
liver may recruit migratory stem cells, particularly 
from the bone marrow, to generate hepatocyte-like 
cells either by transdifferentiation or cell fusion. 
Transplantation of bone marrow stem cells 
(BMSCs) has therapeutic effects of restoration of 
liver mass and function, alleviation of fibrosis and 
correction of inherited liver diseases
35. There are 
still controversial results over the potential effects 
of BMSCs on liver diseases, and some of the 
discrepancies are thought to lie in the differences of 
experimental protocols, differences in individual 
research laboratories, and the uncertainties of the 
techniques employed. Several potential approaches 
for BMSCs delivery in liver diseases have been 
proposed in animal studies and human trials. The 
optimal stem cells delivery route should be easy to 
perform, less invasive and traumatic, minimum side 
effects, and with high cells survival rate
36. 
 
REGENERATIVE MEDICINE 
 
Regenerative medicine is a rapidly growing field of 
biomedicine that seeks to create substitute tissues 
and organs for the human body, to repair or replace 
those whose function is lost through illness, injury, 
aging or congenital anomaly. It is widely accepted 
that regenerative medicine is at the forefront of 21st 
century medical research and represents a 
significant evolution in medical treatment
37. 
Cell-therapies in hepatology have numerous 
advantages when compared to organ liver 
transplant (OLT): the cells can be expanded in 
vitro, genetically manipulated, cryopreserved, 
obtained from the same patient and infused without 
major surgery. Possible cell-based treatments 
consist of hepatocyte transplantation and the 
development of bio-artificial liver systems (BALs). 
BALs have been mainly applied as supportive 
devices in patients excluded from or waiting for 
OLT and hepatocyte transplantation has limited 
overall success, related to the large amount of cells 
required to achieve acceptable function
38. 
Therefore, stem cell-based therapies are emerging 
as new alternatives to OLT for end-stage liver 
pathologies. The most promising source for stem 
cell-based therapies is currently represented by 
BMSCs and/or by mobilizing/proliferating agents, 
such as granulocyte-colony stimulating factor (G-
CSF), which is able to both enhance the BMSC 
mobilization into the peripheral blood and facilitate 
the endogenous liver stem cell activation. BMSCs 
seem to be physiologically involved in the 
processes of liver repair in humans. The possible 
therapeutic potential of these cells has been 
investigated by intraportal autologous 
transplantation of BMSCs, which achieved some 
clinical improvement. However, some authors 
reported negative results regarding BMSC-
therapies for end-stage liver disorders. Other 
clinical approaches have been based upon the 
administration of G-CSF alone or in combination 
with the reinfusion of the mobilized BMSCs. The 
feasibility, safety, and pattern of BMSC 
mobilization following G-CSF treatment in patients 
affected by cirrhosis has been evaluated in a few 
clinical trials
1. 
Overall, the use of adult stem cells (ASCs) for the 
treatment of gastrointestinal and hepatic disorders 
holds several advantages, such as easy 
accessibility, unlimited supply (given the 
possibility to expand the collected cells in vitro) 
and no risks of rejection or need for 
immunosuppressive therapies when autologous 
cells are employed. Nonetheless, some conceptual 
issues still limit the diffusion of such treatments 
into clinical practice. Firstly, on the basis of 
preclinical data, BMSCs seem to facilitate 
gastrointestinal and hepatic regeneration mainly by 
a microenvironment modulation, which is likely to 
be transitory. In such a case, multiple treatments 
would presumably be required to achieve 
significant and lasting clinical results. Moreover, it 
has been observed that in some models of apparent 
transdifferentiation, stem cells may actually be 
fusing with cells in the host tissue. Fusion  Akhtar et al / Stem cells and liver disease 
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phenomena between BMSCs and other cells 
(Purkinje cells, cardiomyocytes and hepatocytes) 
have been shown both in vitro and in vivo
39. The 
implications of this discovery are notable: fusion 
and transdifferentiation are not synonymous, since 
transdifferentiation requires that a specific stem cell 
program be activated on the basis of extracellular 
signals, whereas in the case of fusion, the plasticity 
is trigged by endogenous factors upon mixing of 
the cytoplasm and joining of the nuclei. It must also 
be noted that the fused cells are aneuploid and 
potentially unstable. Consequently, the possibility 
of cell fusion and the risk of malignant 
transformation of the transplanted cells, especially 
those pre-expanded in vitro before re-infusion, 
cannot be excluded and impose a need for careful 
evaluation and longer follow-up periods for 
assessing the safety and efficacy of these stem cell-
based treatments
40. 
 
RISKS OF STEM CELL THERAPY 
 
Most problematic among the risks of stem cell-
based therapies, in addition to the possible rejection 
or loss of function of the infused cells, is their 
potential neoplastic transformation. Indeed, stem 
cells may be used to cure devastating diseases, but 
their specific properties of self-renewal and 
clonogenicity may render them prone to generate 
cancers. Tumor-initiating cells mimic stem cell 
properties to sustain the growth and spread of the 
tumor, while eluding the intrinsic and extrinsic 
controls that regulate homeostasis within stem cell 
populations. The connection between normal stem 
cells and cancer has emerged in many tissues, 
particularly, blood, brain, mammary gland, gut and 
skin. Indeed, that cancer tissues resemble 
developing tissues is a long-standing observation, 
which has suggested a close connection between 
stem cells and cancer. The definitive demonstration 
of cancer stem cells in human neoplasia was first 
made in 1994 in leukaemia. Injection of a small 
subpopulation of acutemyelogenous leukaemia 
cells, identified by a cell surface phenotype also 
found in normal haemopoietic stem cells, caused a 
leukaemia in immunodeficient mice. Importantly, 
the cellular heterogeneity of the resulting 
leukaemia matched that of the patient’s leukaemia. 
The principle of cancer stem cells was then 
extended to solid tumours, first in breast cancer and 
then in brain tumours. In breast cancer, a rare 
fraction of CD44C and CD24lo/K expressing 
human breast cancer cells uniquely caused tumours 
when small numbers of cells were engrafted into 
the mammary fat pads of non-obese diabetic severe 
combined immunodeficient (NOD/SCID) mice
41-43. 
Potential targets for cancer stem cell-based 
therapies in oncology might be found by comparing 
stem cells and cancer stem cell properties.i.e. it is 
well known that cancer stem cells share molecular 
pathways involved in the maintenance of stemness 
(such as Wnt, Sonic Hedgehog, and Notch 
signalling) with stem cells and that they are 
responsive to similar motomorphogens involved in 
both stem cell migration and cancer metastasis. The 
development of drugs antagonizing these signals 
may be helpful in inhibiting cancer stem cell 
proliferation and mobilization, therefore blocking 
cancer growth and metastasis
44. For example, 
Chronic myelogenous leukaemia (CML) is a deadly 
form of leukaemia that is associated with 
chromosome rearrangements that result in the 
expression of the BCR-ABL oncoprotein. 
Treatment of CML with the BCL-ABL inhibitor 
imatinib mesylate (IM, Gleevec) has emerged as 
the first-line treatment for patients with CML,   
However, although most CML patients initially 
respond well to IM treatment, there is evidence that 
primitive quiescent leukaemia stem cells are 
retained in patients achieving remission after IM 
treatment and that these stem cells are responsible 
for disease recurrence. Treatment with histone 
deacetylase inhibitors in combination with imatinib 
mesylate.(HDACis) combined with IM effectively 
induced apoptosis in quiescent CML progenitors 
resistant to elimination by IM alone, and eliminated 
CML stem cells capable of engrafting 
immunodeficient mice in vivo
45. 
 
SUMMARY 
 
Advances in stem cell biology and the discovery of 
pluripotent stem cells have made the prospect of 
cell therapy and tissue regeneration a clinical 
reality. Cell therapies hold great promise to repair, 
restore, replace or regenerate affected organs and 
may perform better than any pharmacological or 
mechanical device. There is an accumulating body 
of evidence supporting the contribution of adult 
stem cells, in particular those of bone marrow 
origin, to liver and pancreatic islet cell 
regeneration. 
Human embryonic stem cell technology could 
solve the organ shortage problem by restoring 
diseased or damaged tissue across a range of 
common conditions. There is an argument in favor 
of encouraging contribution or intentional creation 
of embryos from which widely immunocompatible 
stem cell lines could be derived, towards a global 
human embryonic stem cell bank
46.  
For the next few decades, the global eradication of 
viral hepatitis will be on the agenda. For the 
treatment of inherited and acquired metabolic, toxic 
and immune liver disease, targeted drugs, genes 
and antisense oligonucleotides will be added to our 
therapeutic repertoire.  The widespread use of 
prenatal diagnosis, using DNA chip technology, 
may be expected to cause a dramatic decrease in 
the incidence of inherited diseases. Liver cirrhosis, 
hepatocellular carcinoma and inborn errors of  Akhtar et al / Stem cells and liver disease 
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metabolism may be treated by gene transfer or gene 
repair therapy. Although eventually these 
developments may decrease the need for organ 
transplantation, this by no means is the case yet and 
no solution is available for an increased demand 
and a decreased supply of organs. In the long run, 
diseases caused by multi-drug-resistant infectious 
agents and diseases associated with the abuse of 
alcohol and drugs are expected to become major 
problems. Stem cell research poses many 
challenges but breakthroughs in this field may yield 
not only new forms of treatment, but provide a 
greater understanding of pathological mechanisms. 
The combination of stem cell transplantation and 
gene therapy is a particularly exciting one. Stem 
cell therapy is yet in the experimental stage; a lot of 
data needs to be defined and the clinical application 
has to be carefully monitored. 
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